Analysed COGENT BIOSCIENCES INC (COGT:NASDAQ) News Sources
Cogent Biosciences' Potential Rare Blood Disease Treatment Meets Endpoints in Clinical Trial
12-06-2026
yahoo.com
Cogent Biosciences Announces Detailed Data from APEX Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis at the 2026 European Hematology Association (EHA) Congress
12-06-2026
yahoo.com
Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association (EHA) Congress
12-06-2026
yahoo.com
Is Cogent Biosciences (COGT) ’s New Cancer Drug 100 Times More Precise Than What’s Already on the Market?
22-06-2026
yahoo.com
Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM)
30-06-2026
yahoo.com
Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
15-09-2026
yahoo.com
Will FDA’s Streamlined Bezuclastinib Review in ASM Change Cogent Biosciences’ (COGT) Narrative?
24-09-2026
yahoo.com
What is the current price of COGENT BIOSCIENCES INC (COGT:NASDAQ)?
The current price of COGENT BIOSCIENCES INC (COGT:NASDAQ) is $31.02.
COGENT BIOSCIENCES INC (COGT:NASDAQ) absolute price change since previous trading day?
The absolute price change of COGENT BIOSCIENCES INC (COGT:NASDAQ) since the previous trading day is $-0.94.
COGENT BIOSCIENCES INC (COGT:NASDAQ) percentage price change since previous trading day?
The percentage price change of COGENT BIOSCIENCES INC (COGT:NASDAQ) since the previous trading day is -2.9412%.
What is the most recent average sentiment score for COGENT BIOSCIENCES INC (COGT:NASDAQ)?
The most recent average sentiment score for COGENT BIOSCIENCES INC (COGT:NASDAQ) is 78 out of 100.
What is the most recent average sentiment for COGENT BIOSCIENCES INC (COGT:NASDAQ)?
The most recent sentiment for COGENT BIOSCIENCES INC (COGT:NASDAQ) is .
SEC-8K** Filing Available For COGENT BIOSCIENCES INC (COGT:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.